Sally1のブログ

1. Definition of Parenteral Nutrition

Parenteral nutrition, also referred to as total parenteral nutrition (TPN), denotes the provision of essential nutrients to the body via intravenous infusion, bypassing gastrointestinal absorption entirely. These nutrients encompass amino acids, carbohydrates, fat emulsions, vitamins, and trace elements. For the purposes of this analysis, the scope excludes pure glucose and pure sodium chloride products, as well as multi-packet mixed products combining glucose and sodium chloride. This definitional boundary is critical for market sizing, as it isolates specialized parenteral nutrition formulations from commodity intravenous fluids, thereby capturing the true clinical and commercial value of the parenteral nutrition segment.

2. Global Market Size, Type and Application Market Status and Forecast (2020–2031)

According to the new market research report "Global Parenteral Nutrition Market Report 2025–2031," published by QYResearch, the global parenteral nutrition market size is projected to reach USD 5.8 billion by 2031, at a CAGR of 5.7% during the forecast period. This growth trajectory reflects sustained clinical demand for intravenous nutritional support across critical care, surgical recovery, and chronic illness management. Above data is based on report from QYResearch: Global Parenteral Nutrition Market Report 2025–2031.

According to QYResearch Top Players Research Center, the global key manufacturers of parenteral nutrition include Fresenius Kabi, Baxter, B. Braun, Kelun Pharma, JW Pharmaceutical, and others. In 2024, the global top five players had a share of approximately 52.1% in terms of revenue. This concentration underscores the oligopolistic structure of the parenteral nutrition market, where scale, regulatory approvals, and clinical validation create substantial barriers to entry. Above data is based on report from QYResearch: Global Parenteral Nutrition Market Report 2025–2031.

In terms of product type, Heat and Fat Emulsion is currently the largest segment, holding a share of 61.8%. This dominance reflects the clinical necessity of balanced macronutrient delivery, particularly in intensive care settings where patients require comprehensive caloric and lipid support. Based on or includes research from QYResearch: Global Parenteral Nutrition Market Report 2025–2031.

In terms of product application, One-Chamber is currently the largest segment, holding a share of 72.4%. The prevalence of one-chamber systems reflects their operational simplicity, cost-effectiveness, and compatibility with standard hospital compounding workflows. Based on or includes research from QYResearch: Global Parenteral Nutrition Market Report 2025–2031. The scale of parenteral nutrition in major global markets further illustrates regional variation in adoption, with North America and Europe maintaining mature clinical protocols while Asia-Pacific demonstrates accelerated growth potential. Based on or includes research from QYResearch: Global Parenteral Nutrition Market Report 2025–2031.

3. Market Development of Parenteral Nutrition

3.1 Key Characteristics of Industry Development

1) Huge Market Potential

While China's parenteral nutrition market has achieved remarkable results in recent years, significant growth potential remains. With increasing health awareness and a growing aging population, the parenteral nutrition market will continue its rapid growth, providing patients with better nutritional treatment options. With economic development and the improvement of the medical insurance system, the potential of the parenteral nutrition market is gradually being released, leading to sustained growth in market demand.

2) Clinical Guidelines and Standards

As research and understanding of parenteral nutrition deepen, more and more clinical guidelines and standards are being developed, guiding clinicians to use parenteral nutrition more scientifically and rationally, thus improving its application level. Recent updates to ESPEN and ASPEN guidelines have further refined recommendations for lipid emulsions, amino acid formulations, and micronutrient supplementation, creating a more structured demand environment for compliant products.

3) Policy Support

Increasing government investment in the healthcare sector and supportive policies also benefit the research, development, production, and promotion of parenteral nutrition products. In China, the inclusion of parenteral nutrition in national medical insurance reimbursement lists has accelerated hospital adoption, while in the United States, CMS reimbursement pathways for home parenteral nutrition support have expanded the addressable patient population.

4) Advances in Medical Technology

Advances in medical technology, especially in critical care medicine and surgical techniques, enable more patients who were previously unable to eat to maintain their nutritional status through parenteral nutrition, improving their survival rate and quality of life. The integration of parenteral nutrition into enhanced recovery after surgery (ERAS) protocols represents a particularly notable development, with perioperative nutritional optimization now recognized as a key determinant of surgical outcomes.

3.2 Analysis of Factors Affecting Industry Development

1) Analysis of Favorable Factors for the Development of the Parenteral Nutrition Industry

Increased Health Awareness: Increased public health awareness has led to greater emphasis on nutrition and health, increasing the demand for nutritional supplements and rehabilitation support, thus driving the development of the parenteral nutrition industry.

Aging Population: With the intensifying global trend of population aging, the number of malnourished and chronically ill elderly individuals is increasing, leading to a continuous rise in demand for parenteral nutrition. By 2030, one in six people worldwide will be aged 60 or over, according to UN projections, creating a structural demand tailwind for clinical nutrition products.

Technological Innovation: The research and development of new parenteral nutrition products, such as synthetic parenteral nutrition formulas and the application of nanotechnology in parenteral nutrition, provides new impetus for the industry's development. Recent innovations include fish-oil-based lipid emulsions with anti-inflammatory properties, olive-oil-based formulations with improved oxidative stability, and ready-to-use multi-chamber bags that reduce compounding errors.

International Cooperation: Global academic exchanges and cooperation help promote the development of parenteral nutrition technology and also provide domestic companies with opportunities to learn from and draw on international best practices.

2) Analysis of Unfavorable Factors for Industry Development

Product Homogenization: Competition in the amino acid product market is fierce, and products from various companies are relatively homogeneous. This commoditization pressure is particularly acute in generic amino acid solutions, where price competition erodes margins and limits reinvestment in differentiation.

Declining Gross Profit Margin: Continuously rising labor and raw material costs, coupled with the difficulty in keeping product prices up, have led to a continuous decline in the company's gross profit margin. This margin compression is especially pronounced for manufacturers lacking proprietary formulation or delivery-system intellectual property.

Exchange Rate Fluctuation Risk: In recent years, affected by US monetary policy, the exchange rates of local currencies against the US dollar in most parts of the world have fluctuated significantly, causing great uncertainty for enterprises' raw material imports and overseas sales, increasing operational risks and posing a significant challenge to normal business operations.

3.3 Market Challenges

1) Technological Barriers

Parenteral nutrition manufacturing involves various materials and processes, requiring significant technological expertise and R&D capabilities. Smaller brands may struggle to overcome these technological barriers and produce high-quality, stable parenteral nutrition. Furthermore, parenteral nutrition products must obtain drug approval in the regions or countries where they are sold. The complexity of achieving sterility assurance, particulate control, and long-term stability across multi-component formulations creates a formidable technical moat.

2) Brand and Channel Barriers

The parenteral nutrition industry has established strong brand and channel advantages. Well-known brands and channels enjoy high market share and positive reputations. New entrants need time and effort to gain market share. Hospital formulary committees and group purchasing organizations (GPOs) in major markets tend to favor established suppliers with proven clinical track records, creating a self-reinforcing advantage for incumbents.

3) Capital Barriers

Parenteral nutrition manufacturing requires substantial capital investment, including equipment procurement, raw material procurement, and production costs. New entrants need sufficient financial strength and financing capabilities to meet production and market expansion needs. Aseptic filling lines, lyophilization equipment, and validated cleanroom facilities represent significant fixed-cost commitments that demand long-term volume certainty.

4) Quality Control Barriers

The quality and performance of parenteral nutrition directly impact consumer experience and reputation. Therefore, quality control is a crucial barrier to entry into the parenteral nutrition industry. New entrants need to establish a comprehensive quality control system to ensure the stability and consistency of product quality and performance. Given that parenteral nutrition is administered directly into the bloodstream, deviations in sterility, endotoxin levels, or particulate matter can have life-threatening consequences, making regulatory scrutiny exceptionally rigorous.

Contact Us

If you have any queries regarding this report or if you would like further information, please contact us:

QY Research Inc.

Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States

EN: https://www.qyresearch.com

E-mail: global@qyresearch.com

Tel: 001-626-842-1666(US)

JP: https://www.qyresearch.co.jp